Heading into an FDA hearing on Monday regarding the future of psychedelic treatments, public comments show wide support for further exploring the therapeutic potential of these compounds—to match rising support within the agency.
A highly anticipated FDA hearing to discuss psychedelic drug development on Monday is preceded by robust public support for the class and the Trump administration’s efforts to allow more of them to reach the market, according to analysts. It also directly follows the appointment of FDA leaders expected to be friendly to the emerging drug class.
“We think key stakeholders already sound supportive,” Jefferies analysts wrote in a note to clients last week, adding that this list includes patients, doctors, interventional psychiatry centers, the FDA and Department of Health and Human Services (HHS), the White House and Veterans Affairs (VA). “An engaged/constructive ecosystem should benefit the potential psychedelic launches in 2027+.”
The first potential launch could belong to Compass Pathways’ psilocybin-based depression candidate COMP360, which is widely expected to receive FDA approval via the new Commissioner’s National Priority Voucher program by the end ...